NASDAQ:ALGS
Aligos Therapeutics Inc. Stock News
$0.689
+0.0335 (+5.11%)
At Close: May 17, 2024
SOUTH SAN FRANCISCO, Calif., Oct. 21, 2022 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address
Aligos Therapeutics to Announce Third Quarter Results November 2, 2022
04:15pm, Wednesday, 19'th Oct 2022
SOUTH SAN FRANCISCO, Calif., Oct. 19, 2022 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, the “Company”), a clinical stage biopharmaceutical company focused on developing novel thera
Aligos' pan-Coronavirus inhibitor, ALG-097558, is on track to begin first clinical studies in 1H 2023 Aligos' pan-Coronavirus inhibitor, ALG-097558, is on track to begin first clinical studies in 1H 2
Aligos Therapeutics to Present at the Jefferies 2022 Healthcare Conference
04:05pm, Monday, 23'rd May 2022
SOUTH SAN FRANCISCO, Calif., May 23, 2022 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address u
Aligos Therapeutics to Announce First Quarter 2022 Results May 4, 2022
04:05pm, Wednesday, 27'th Apr 2022
SOUTH SAN FRANCISCO, Calif., April 27, 2022 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address
Aligos Therapeutics to Announce Fourth Quarter and Full Year 2021 Results March 10, 2022
04:05pm, Wednesday, 02'nd Mar 2022
SOUTH SAN FRANCISCO, Calif., March 02, 2022 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address
Aligos (ALGS) Stock Down on Hepatitis Drug Development Halt
01:49pm, Friday, 07'th Jan 2022
Aligos Therapeutics' (ALGS) phase I study evaluating its chronic hepatitis B candidate, ALG-010133, did not achieve sufficient activity against the disease.
Aligos Therapeutics Stock (ALGS): Why The Price Substantially Fell
09:00am, Friday, 07'th Jan 2022
The stock price of Aligos Therapeutics Inc (NASDAQ: ALGS) fell by 56.74% in the most recent trading session. This is why it happened.
Why Aligos Therapeutics Stock Crumbled Today
06:21pm, Thursday, 06'th Jan 2022
The company is pulling the plug on a once-promising treatment targeting hepatitis B.
Aligos Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference
04:05pm, Tuesday, 21'st Dec 2021
SOUTH SAN FRANCISCO, Calif., Dec. 21, 2021 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address
Aligos Therapeutics to Present at the Piper Sandler 33rd Annual Virtual Healthcare Conference
08:00am, Monday, 22'nd Nov 2021
SOUTH SAN FRANCISCO, Calif., Nov. 22, 2021 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address
All You Need to Know About Aligos Therapeutics, Inc. (ALGS) Rating Upgrade to Buy
01:45pm, Tuesday, 09'th Nov 2021
Aligos Therapeutics, Inc. (ALGS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Aligos Therapeutics to Present Data for its Clinical Portfolio Targeting Chronic Hepatitis B and NASH at AASLD'S The Liver Meeting® 2021
04:58pm, Thursday, 14'th Oct 2021
SOUTH SAN FRANCISCO, Calif., Oct. 14, 2021 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address
Aligos now evaluating three of its four chronic hepatitis B (CHB) portfolio drug candidates in clinical trials Aligos now evaluating three of its four chronic hepatitis B (CHB) portfolio drug candidat
Aligos Therapeutics to Present at the Cantor Virtual Global Healthcare Conference
04:05pm, Monday, 20'th Sep 2021
SOUTH SAN FRANCISCO, Calif., Sept. 20, 2021 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address
